Raia DrogasilBSP:RADL3 +3.53%91 EBIT per Share is R$1.52 as of Mar. 2026. GuruFocus rates BSP:RADL3 with a GF Score™ of 91/100 and a GF Value™ of R$29.98 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 529 Healthcare Providers & Services companies, Raia Drogasil ranks better than 50.66% on this metric.
Raia Drogasil's EBIT per Share for the
three
months ended in Mar. 2026 was R$0.25.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was R$1.52.
During the past 12 months, the average EBIT per Share Growth Rate of Raia Drogasil was 21.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 13.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 24.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 18.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Raia Drogasil's EBIT per Share or its related term are showing as below:
BSP:RADL3'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -9.8 Med: 25.5 Max: 98.3
Current: 13
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Raia Drogasil was 98.30% per year. The lowest was -9.80% per year. And the median was 25.50% per year.
BSP:RADL3's 3-Year EBIT Growth Rate is ranked better than 50.66% of 529
companies
in the Healthcare Providers & Services industry
Industry Median: 12.1
vs BSP:RADL3: 13.00
Raia Drogasil's EBIT for the
three
months ended in Mar. 2026 was R$425 Mil.
Raia Drogasil (BSP:RADL3) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Raia Drogasil EBIT per Share Related Terms
Raia Drogasil EBIT per Share Historical Data
* Premium members only.
The historical data trend for Raia Drogasil's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1.52
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raia Drogasil (BSP:RADL3) has a EBIT per Share of R$1.52 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Raia Drogasil and its competitors. According to the industry distribution chart, Raia Drogasil ranks #261 out of 529 companies in the Healthcare Providers & Services industry, placing it in the top 49.3%.
Is Raia Drogasil's EBIT per Share too high?
Raia Drogasil's current EBIT per Share is R$1.52. Based on the distribution chart, Raia Drogasil ranks #261 out of 529 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Raia Drogasil has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's EBIT per Share compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #261 out of 529 companies for EBIT per Share. This puts Raia Drogasil in the upper half of its industry. The industry median EBIT per Share is 12.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.10, based on 529 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Raia Drogasil and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current EBIT per Share is R$1.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$29.98, compared to a current price of R$18.77 — trading 37.4% below its estimated fair value. The current EBIT per Share is R$1.52. Raia Drogasil's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current EBIT per Share is R$1.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$18.77 is trading 37.4% below its estimated GF Value™ of R$29.98.
GuruFocus considers Raia Drogasil to be Significantly Undervalued.
Key valuation signals for BSP:RADL3:
EBIT per Share: R$1.52
GF Value™: R$29.98 vs. price of R$18.77 (37.4% below fair value)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
91GF Score
Get the complete analysis for BSP:RADL3
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
